Navigation Links
Laureate Announces Manufacturing Agreement with Tolerx
Date:10/21/2008

-Laureate to Manufacture Tolerx's TRX518 Antibody

PRINCETON, N.J., Oct. 21 /PRNewswire/ -- Laureate Pharma, Inc., a full- service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases. Under the agreement, Laureate will produce Tolerx's humanized anti-GITR antibody known as TRX518, which is currently in development for cancer and chronic viral indications. Details of the agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO)

"The partnership with Tolerx validates the progress we have made in biomanufacturing and our commitment in helping our clients bring novel therapies to the market," said Robert J. Broeze, Ph.D., President & Chief Executive Officer of Laureate. "With our well established monoclonal antibody experience, we will partner closely with the Tolerx team to help them achieve their manufacturing objectives."

"Laureate Pharma has a proven track record in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials," said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx. "This agreement enables us to operationally leverage Laureate's expertise and infrastructure while we seek to establish new treatment paradigms in the immunology space."

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com.

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. TRX518 is directed to GITR and is in preclinical development for the treatment of cancer and chronic viral diseases. TRX518 is thought to circumvent immune system tolerance by inhibiting the suppressive activity of T regulatory cells and extending the survival of T effector cells, thereby enhancing responses to tumor and viral antigens. Tolerx also has two antibodies in clinical development for the treatment of various autoimmune indications, these are: otelixizumab, an anti-CD3 MAb that is being developed in collaboration with GlaxoSmithKline and MTRX1011A a modified form of TRX1, an anti-CD4 MAb that is being developed in collaboration with Genentech, Inc. In addition to TRX518, Tolerx is also engaged in the preclinical development of other antibodies that may shift or modulate the immune system. For more information, please visit http://www.tolerx.com.


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Thomson Scientific Salutes Nobel Laureate Prize Winners, Many of Whom Were Selected as Thomson Scientific Laureates in 2006
2. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. Laureate Pharma Appoints Gary Swan as Vice President of Operations
6. Laureate Pharma Reports Record Growth for 2007
7. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
8. ARUP Laboratories ARUP Consult(R) Recognized as a Computerworld Honors Program Laureate
9. Laureate Pharma to Add More Manufacturing Capacity
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... NY (PRWEB) , ... October 12, 2017 , ... ... of Sciences today announced the three Winners and six Finalists of the 2017 ... given annually by the Blavatnik Family Foundation and administered by the New York ...
(Date:10/12/2017)... ... 12, 2017 , ... AMRI, a global contract research, development ... patient outcomes and quality of life, will now be offering its impurity solutions ... new regulatory requirements for all new drug products, including the finalization of ICH ...
(Date:10/11/2017)... ... , ... Personal eye wash is a basic first aid supply for any work environment, but ... do you rinse first if a dangerous substance enters both eyes? It’s one less decision, ... its unique dual eye piece. , “Whether its dirt and debris, or an acid or ...
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
Breaking Biology News(10 mins):